Please login to the form below

Not currently logged in
Email:
Password:

heart failure therapy

This page shows the latest heart failure therapy news and features for those working in and with pharma, biotech and healthcare.

Novartis negotiates ex-US rights to Spark gene therapy

Novartis negotiates ex-US rights to Spark gene therapy

Gene therapy is a promising new avenue to potentially address this unmet need.”. ... The gains were driven by strong performances from new immunotherapy Cosentyx (secukinumab), which breached the $2bn sales threshold for the year, as well as heart

Latest news

  • Celixir cleared to start trial of stem cell therapy for heart failure Celixir cleared to start trial of stem cell therapy for heart failure

    Celixir cleared to start trial of stem cell therapy for heart failure. ... Heart failure is still a major cause of death affecting millions of patients worldwide [and] current therapies do not reduce chronic myocardial scarring, diminish disease

  • Alcon spin-out more likely but not imminent, says Novartis Alcon spin-out more likely but not imminent, says Novartis

    Alcon re-emerged as one of the engines of Novartis’growth in the third quarter along with fast-growing psoriasis blockbuster Cosentyx (secukinumab) and heart failure therapy Entresto (sacubitril/valsartan), which

  • Vifor wins European approval for Veltassa Vifor wins European approval for Veltassa

    therapy due to heart failure and/or chronic kidney disease. ... RAAS inhibitors can also lead to elevated potassium levels, which can lead to organ failure, however researchers have found patiromer can reduce potassium levels.

  • CV data sets up Novartis' Ilaris for blockbuster sales CV data sets up Novartis' Ilaris for blockbuster sales

    with a prior heart attack and inflammatory atherosclerosis when added to standard therapy. ... chronic heart failure therapy Entresto (sacubitril/valsartan) - also predicted to become a blockbuster but currently growing slowly thanks largely to payer

  • What future for serelaxin after phase III miss? What future for serelaxin after phase III miss?

    What future for serelaxin after phase III miss? Novartis' acute heart failure therapy misses two main endpoints. ... The failure of Novartis' acute heart failure therapy serelaxin to hit its objectives in a second phase III trial is somewhat embarrassing

More from news
Approximately 0 fully matching, plus 30 partially matching documents found.

Latest Intelligence

  • Can value-based healthcare take off and reach for the skies? Can value-based healthcare take off and reach for the skies?

    CAR-T cell therapy for children with B-cell ALL. ... costs. It was then backed with a ‘no response-no payment’contract. It has also struck novel reimbursement packages with its heart failure therapy Entresto and its psoriasis treatment Cosentyx.

  • Heart failure therapy embarks on a new era Heart failure therapy embarks on a new era

    Heart failure therapy embarks on a new era. After years of older, generic drugs, now new treatments are showing promising results. ... failure by 18% compared to placebo when given on top of standard HF therapy.

  • Pharma deals in April 2015 Pharma deals in April 2015

    uniQure has licensed its proprietary gene therapy programme for congestive heart failure, that is hoped will restore the heart's ability to synthesise S100A1, a calcium sensor and master regulator of ... to become available for common diseases such as

  • Pharma deals during October 2013 Pharma deals during October 2013

    80. Celladon. Mydicar gene therapy for heart failure (phase IIb). 75. ... 75. Trevena. TRV027, GPCR biased ligand for acute heart failure (phase II).

More from intelligence
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest appointments

  • uniQure appoints chief executive officer uniQure appoints chief executive officer

    Kapusta had previously served as the gene therapy specialist's interim chief executive since September last year, as well as chief financial officer since January 2015. ... for congestive heart failure and Huntington's disease into the clinic.”.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete HealthVizion

Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics